
Lord O’Shaughnessy Review: Boosting UK Clinical Trials
Following the publishing of Lord O’Shaughnessy’s review, we examine the response of the Government to action the important recommendations to boost clinical trials.
Following the publishing of Lord O’Shaughnessy’s review, we examine the response of the Government to action the important recommendations to boost clinical trials.
A third of people with symptoms of Dementia are reportedly keeping concerns to themselves. We examine the landscape of the disease ahead of Curia’s inquiry session on future dementia technologies.
The United Kingdom and India are set to sign a landmark agreement on science, research and innovation that will see several new innovative research programmes
Recently, Chamber hosted the first of its regional Integrating Healthcare Seminar series, in partnership with IQVIA. This was held in Manchester where MPs and the Shadow Minister for
During the successful Integrating Healthcare seminar in Manchester, Chris Green gave his address to the audience of NHS, life science and national/local government leaders.
Maria Caulfield MP, Minister for Mental Health and Women’s Health and the Minister for Women writes for Chamber on placing women’s health at the top of the Government’s agenda.
The Chancellor’s budget statement announced new funding for the MHRA, we examine the impact for the health and life sciences sector.
The Prime Minister and Technology Secretary today unveiled the Government’s plan to “cement the UK’s place as a science and technology superpower by 2030.”
Last year, the government published the first-ever Rare Diseases Action Plan for England. It set out to ensure that those living with rare diseases in England receive the best possible care and to improve accurate diagnoses for patients suffering from unknown diseases.
The Government has announced new plans to modernise the regulatory environment in health and life sciences, we examine the potential benefit to ensure NHS pressures are alleviated and life sciences can achieve its potential.
Government commissions independent commercial clinical trials review from Lord James O’Shaughnessy.
The Government has announced a new strategy to boost access to medtech innovations in the UK, we examine the outlook for the sector and patients from the new plans.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Receive our latest insights and all future journals as soon as they are published and get invited to our exclusive events and webinars.
We respect your privacy and will not share your email address with any third party. Your personal data will be collected and handled in accordance with our Privacy Policy.
Receive our latest insights and all future journals as soon as they are published and get invited to our exclusive events and webinars.
We respect your privacy and will not share your email address with any third party. Your personal data will be collected and handled in accordance with our Privacy Policy.
Receive our latest insights as soon as they are published and get invited to our exclusive events and webinars.
We respect your privacy and will not share your email address with any third party. Your personal data will be collected and handled in accordance with our Privacy Policy.